Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial.

Moinpour CM, Darke AK, Donaldson GW, Thompson IM Jr, Langley C, Ankerst DP, Patrick DL, Ware JE Jr, Ganz PA, Shumaker SA, Lippman SM, Coltman CA Jr.

J Natl Cancer Inst. 2007 Jul 4;99(13):1025-35. Epub 2007 Jun 27.

PMID:
17596576
2.
3.

Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.

Lotan Y, Cadeddu JA, Lee JJ, Roehrborn CG, Lippman SM.

J Clin Oncol. 2005 Mar 20;23(9):1911-20. Review.

PMID:
15774783
4.

Five-alpha-reductase Inhibitors for prostate cancer prevention.

Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD007091. doi: 10.1002/14651858.CD007091. Review.

PMID:
18425978
5.

The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.

Andriole G, Bostwick D, Civantos F, Epstein J, Lucia MS, McConnell J, Roehrborn CG.

J Urol. 2005 Dec;174(6):2098-104. Review.

PMID:
16280736
6.

Prostate cancer prevention and finasteride.

D'Amico AV, Barry MJ.

J Urol. 2006 Nov;176(5):2010-2; discussion 2012-3. Review.

PMID:
17070238
7.

Should finasteride be used to prevent prostate cancer?

Fleshner N, Kulkarni G.

Curr Treat Options Oncol. 2006 Sep;7(5):346-54. Review.

PMID:
16904051
8.

Update on chemoprevention of prostate cancer.

Klein EA, Thompson IM.

Curr Opin Urol. 2004 May;14(3):143-9. Review.

PMID:
15069304
9.

Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention.

Canby-Hagino E, Hernandez J, Brand TC, Thompson I.

Eur Urol. 2007 Jan;51(1):27-33. Epub 2006 Sep 15. Review.

PMID:
17030406
10.

Prevention of prostate cancer with finasteride: US/European perspective.

Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B.

Eur Urol. 2003 Dec;44(6):650-5. Review.

PMID:
14644115
11.

Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice.

Goetzl MA, Holzbeierlein JM.

Nat Clin Pract Urol. 2006 Aug;3(8):422-9. Review.

PMID:
16902518
12.

The finasteride prostate cancer prevention trial (PCPT)--what have we learned?

Mellon JK.

Eur J Cancer. 2005 Sep;41(13):2016-22. Review.

PMID:
16061372
13.

The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.

Reed AB, Parekh DJ.

Curr Opin Urol. 2009 May;19(3):238-42. doi: 10.1097/MOU.0b013e328329eb29. Review.

PMID:
19318950
14.

Screening for prostate cancer: opportunities for prevention.

Thompson IM, Coltman CA.

Semin Urol Oncol. 1996 May;14(2 Suppl 2):4-10; discussion 10-1. Review.

PMID:
8725886
15.

Prostate cancer: a serious disease suitable for prevention.

Fitzpatrick JM, Schulman C, Zlotta AR, Schröder FH.

BJU Int. 2009 Apr;103(7):864-70. doi: 10.1111/j.1464-410X.2008.08206.x. Review.

16.

A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.

Montorsi F, Alcaraz A, Desgrandchamps F, Hammerer P, Schröder F, Castro R.

Prostate. 2009 Jun 1;69(8):895-907. doi: 10.1002/pros.20939. Review.

PMID:
19267353
18.

The clinical implications of the prostate cancer prevention trial.

Marberger M, Adolfsson J, Borkowski A, Fitzpatrick J, Kirk D, Prezioso D, Rabaça C, Solsona E, Teillac P.

BJU Int. 2003 Nov;92(7):667-71. Review. No abstract available.

19.

Healthcare resources should be targeted to chemoprevention: the argument against.

Trachtenberg J.

Eur Urol. 1996;29 Suppl 2:17-8. Review.

PMID:
8717455
20.

The Prostate Cancer Prevention Trial: current status.

Higgins B, Thompson IM.

J Urol. 2004 Feb;171(2 Pt 2):S15-7; discussion S8. Review.

PMID:
14713747

Supplemental Content

Support Center